ATE557102T1 - Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit - Google Patents
Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheitInfo
- Publication number
- ATE557102T1 ATE557102T1 AT10003542T AT10003542T ATE557102T1 AT E557102 T1 ATE557102 T1 AT E557102T1 AT 10003542 T AT10003542 T AT 10003542T AT 10003542 T AT10003542 T AT 10003542T AT E557102 T1 ATE557102 T1 AT E557102T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- diagnosing
- multiple sclerosis
- predicting
- effectiveness
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06003978A EP1826277A1 (de) | 2006-02-27 | 2006-02-27 | Methoden zur Vorhersage der Wirksamkeit von Interferon Therapie bei Multiple Sklerose Patienten und Methoden zur Diagnose der Krankheit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE557102T1 true ATE557102T1 (de) | 2012-05-15 |
Family
ID=36658688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07711702T ATE466959T1 (de) | 2006-02-27 | 2007-02-27 | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose |
| AT10003542T ATE557102T1 (de) | 2006-02-27 | 2007-02-27 | Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07711702T ATE466959T1 (de) | 2006-02-27 | 2007-02-27 | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8071299B2 (de) |
| EP (4) | EP1826277A1 (de) |
| AT (2) | ATE466959T1 (de) |
| DE (1) | DE602007006284D1 (de) |
| DK (2) | DK1991696T3 (de) |
| SI (1) | SI2196545T1 (de) |
| WO (1) | WO2007096197A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110008290A1 (en) * | 2007-11-09 | 2011-01-13 | David Brassat | Method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon |
| CA2724420A1 (en) * | 2008-07-24 | 2010-01-28 | Merck Serono S.A. | Use of genetic markers for identifying the response to interferon treatment in multiple sclerosis patients |
| WO2011117267A1 (en) * | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2380992A1 (de) * | 2010-04-21 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur Vorhersage einer Antikörperreaktion auf eine Interferon-Therapie bei Patienten mit multipler Sklerose |
| CN110494880A (zh) * | 2017-01-27 | 2019-11-22 | 欧瑞3恩公司 | 基于个人基因轮廓来判定和展现购买建议的系统和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1114998A3 (de) | 1999-10-28 | 2001-08-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Verfahren zur Bestimmung von Erfolgsquote von Multiple Sklerose-Behandlung |
| WO2003014319A2 (en) | 2001-08-07 | 2003-02-20 | Genaissance Pharmaceuticals, Inc. | Polymorphisms associated with multiple sclerosis |
| SE0103423D0 (sv) | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
| GB0307914D0 (en) | 2003-04-07 | 2003-05-14 | Univ Dundee | Cytochrome p450 |
| CA2549913A1 (en) * | 2003-11-26 | 2005-06-16 | The Ohio State University Research Foundation | Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression |
-
2006
- 2006-02-27 EP EP06003978A patent/EP1826277A1/de not_active Withdrawn
-
2007
- 2007-02-27 SI SI200730969T patent/SI2196545T1/sl unknown
- 2007-02-27 DK DK07711702.6T patent/DK1991696T3/da active
- 2007-02-27 EP EP10003543A patent/EP2196546B1/de not_active Not-in-force
- 2007-02-27 AT AT07711702T patent/ATE466959T1/de not_active IP Right Cessation
- 2007-02-27 AT AT10003542T patent/ATE557102T1/de active
- 2007-02-27 EP EP07711702A patent/EP1991696B1/de not_active Not-in-force
- 2007-02-27 DK DK10003542.7T patent/DK2196545T3/da active
- 2007-02-27 EP EP10003542A patent/EP2196545B1/de not_active Not-in-force
- 2007-02-27 WO PCT/EP2007/001689 patent/WO2007096197A2/en not_active Ceased
- 2007-02-27 DE DE602007006284T patent/DE602007006284D1/de active Active
- 2007-02-27 US US12/280,665 patent/US8071299B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007096197A2 (en) | 2007-08-30 |
| EP2196546B1 (de) | 2013-02-27 |
| US8071299B2 (en) | 2011-12-06 |
| DK1991696T3 (da) | 2010-08-30 |
| EP1826277A1 (de) | 2007-08-29 |
| EP1991696B1 (de) | 2010-05-05 |
| WO2007096197A3 (en) | 2007-10-18 |
| US20090186773A1 (en) | 2009-07-23 |
| SI2196545T1 (sl) | 2012-09-28 |
| DK2196545T3 (da) | 2012-07-16 |
| EP2196546A1 (de) | 2010-06-16 |
| DE602007006284D1 (de) | 2010-06-17 |
| EP2196545A1 (de) | 2010-06-16 |
| EP2196545B1 (de) | 2012-05-09 |
| ATE466959T1 (de) | 2010-05-15 |
| EP1991696A2 (de) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413902T1 (de) | Patientenüberwachungssystem | |
| BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
| ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
| DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| ATE466959T1 (de) | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose | |
| DK1715890T3 (da) | CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati | |
| DE10390950D2 (de) | Vorrichtung zur Behandlung von Patienten mittels Hirnstimulation | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| DE502006007982D1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
| EP2287340A3 (de) | Verfahren zur Diagnose und Behandlung einer Geisteskrankheit | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE478335T1 (de) | Verfahren in echtzeit zur erkennung von akuten entzündungszuständen | |
| WO2007087646A3 (en) | Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia | |
| EP1496743A4 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| ATE551067T1 (de) | Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen | |
| DE602006018145D1 (de) | Verfahren zur diagnose und behandlung auf nr2-peptiden beruhender zerebrovaskulärer ereignisse | |
| DE602006015221D1 (de) | Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression | |
| ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
| ATE546548T1 (de) | Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten | |
| MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. |